Cmbio®, a global leader in multi-omics science and digital biology, is pleased to announce the purchase of the e[datascientist]™ software platform through an Asset Sale Agreement with CBW Recovery LLP and Eagle Genomics Limited (In Administration).
Eagle Genomics, founded in 2008 and based in Cambridge, UK is renowned for its enterprise cloud software platform that facilitates data-intensive research in life sciences. The company’s platform provides an intuitive approach to curating, integrating, sharing, analyzing, and valuing complex scientific data.
The Asset Sale Agreement includes all intellectual property related to Eagle Genomics‘ business. This strategic transaction aligns well with Cmbio®’s mission to advance multi-omics science and technology, enabling scientists across industry and academia to access its advanced bioinformatics and AI/ML toolbox through scalable, robust and validated software solutions.
